A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
about
Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysisResponse to degarelix after resistance to leuprolide in a patient with metastatic prostate cancerThe role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UKAdvances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapyDegarelix as a new antiangiogenic agent for metastatic colon cancer?Drivers for change in the management of prostate cancer - guidelines and new treatment techniques.Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directionsThe follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.Androgen deprivation therapy: past, present and future.New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Triptorelin in the management of prostate cancer.Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?The transcriptional programme of the androgen receptor (AR) in prostate cancer.Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer.Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?Degarelix: a review of its use in patients with prostate cancer.Novel agents in the management of castration resistant prostate cancer.Advances in systemic therapies for metastatic castration-resistant prostate cancer.Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl.Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist.Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patientsEfficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)Is bilateral orchiectomy for metastatic prostate cancer treatment associated with high cardiovascular risk?Luteinizing hormone-releasing hormone antagonists for urinary obstruction in prostate cancer.Experience with degarelix in the treatment of prostate cancer.Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et al.Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patientsCost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
P2860
Q26777150-8B07CDF8-D0AD-462A-9979-73D6B44AAFAEQ27022516-676B5D7E-C0A5-4EEF-82E7-FC2F1BF91906Q28072710-008BDCCC-7B78-4FFE-9FF7-66C69E17EE1DQ28829239-CB7EC38E-3089-42BC-9D34-FB26641C0663Q30458111-5FA0D637-C30F-418B-8B36-9B7ECA41C762Q34294112-B8107C77-D47A-480A-A7A2-4C66BB619CC8Q34636636-B9DB1534-5DCC-4F64-BC27-8E0DB0532D61Q35683334-055CCAA2-5D96-4590-8B46-1DA6CA658BFEQ35870468-FEBE690A-E49B-415E-8870-74C3AF3CCAFAQ35879087-4314D5A0-555E-465A-A01A-CF6A50389754Q36070721-9A465754-1B0F-4E0A-A91A-A17DF790E973Q36748502-25CEBB32-8D63-4827-A0C5-D06CCD0329AEQ36760953-95E3EC79-90D9-4687-AA46-7CBA5D11F8CEQ38003528-2B7CD0D1-3AD9-4594-B633-C82E7190C093Q38016530-ED551132-E290-4AC2-88E1-68917DD9B9E0Q38023124-840BB8C3-9600-4A08-B1C1-26BEBF765235Q38068495-A129A71A-2713-4D5B-A52C-5120B99B4AA9Q38082516-A9347C71-6A42-4198-8622-2D6913CB3DB7Q38140106-B62B762B-8219-469B-BDAB-E15F899F560AQ38193002-5FEE5CB4-C680-4B8C-876A-9CBD1D46F767Q38195921-DAB51851-B56C-4B25-9178-A057DCEC9017Q38206404-34CAD0AF-81AA-495D-AEBC-AF06B9A5216AQ38209656-DDB3ECF6-BC90-443D-863F-09F22F805ACCQ38282461-BDF18E58-CF29-4A03-9307-7BEBDCB2D042Q38619233-D86DDD23-E96A-460A-87C4-0080C7DC7A1EQ38798811-98C58441-6954-454A-A780-438330619541Q38892158-84A0AD16-4775-4754-BE2C-DC26AF430215Q38969625-932A040F-4A83-4BCC-8E5C-937FEBE81D2EQ39247489-A3E52F83-F51B-4F93-A80D-AB31BF5634A8Q40018470-25297B2D-FF50-44C3-BFD9-E3D88C42F59BQ41450374-F1F25E81-F3F2-45BE-B04B-653AAC9DAFAAQ41508304-3F73B3C3-E697-4293-A720-E42F5CEDFA07Q41555086-FC71C4BD-804F-4E46-B5B4-2FFB36C8D7BDQ41600644-750F55D6-67FE-4F00-B964-3496EB0D718BQ41820745-3E63AD05-7E5B-4C33-A955-EA8F8D9E20F5Q41861437-EA34BAE5-90CF-4E5F-82CB-83DA4B8C2D35Q42029952-81E52FBE-5BE4-41DE-9F3D-AA1DD7CDA0A6Q42540042-6F27ECB5-10D9-4288-A898-A393E12C5C57Q42654761-30DB19B6-60B9-4077-A95E-268A922D693CQ46077022-E6D3466C-B8A8-4FF0-B23B-870D321774B0
P2860
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase III extension trial wi ...... ist effect on prostate cancer.
@ast
A phase III extension trial wi ...... ist effect on prostate cancer.
@en
A phase III extension trial wi ...... ist effect on prostate cancer.
@nl
type
label
A phase III extension trial wi ...... ist effect on prostate cancer.
@ast
A phase III extension trial wi ...... ist effect on prostate cancer.
@en
A phase III extension trial wi ...... ist effect on prostate cancer.
@nl
prefLabel
A phase III extension trial wi ...... ist effect on prostate cancer.
@ast
A phase III extension trial wi ...... ist effect on prostate cancer.
@en
A phase III extension trial wi ...... ist effect on prostate cancer.
@nl
P2093
P1476
A phase III extension trial wi ...... nist effect on prostate cancer
@en
P2093
Bo-Eric Persson
E David Crawford
Fritz Schröder
Jens-Kristian Jensen
Judd W Moul
Kurt Miller
Laurent Boccon-Gibod
Neal Shore
Tine Kold Olesen
P304
P356
10.1016/J.JURO.2011.04.083
P407
P577
2011-07-23T00:00:00Z